President, Rockefeller University
President and CEO, Burnham Institute for Medical Research
Founder and Director, Pinwheel Diagnostics Inc.
Founding Partner, General Assembly
President, University of Texas MD Anderson Cancer Center
Co-Founder and Managing Director, ARCH Venture Partners
Founding Director, Massachusetts Technology Transfer Center
Managing Partner, Rho Capital Partners and Rho Ventures
|
|
AVI Biopharma, a Portland, OR-based developer of RNA-based drugs, said today it has secured a contract with the U.S. Defense Threat Reduction Agency to develop drugs for H1N1, or swine flu. Under the contract, worth as much as $5.1 million, AVI will analyze the H1N1 sequence, determine appropriate targets and identify lead and back-up candidate drugs. The company (NASDAQ: AVII) also plans to do animal tests.
San Francisco · 6/3/13
Xconomy offers a number of ways to subscribe for free!
Subscribe Now
Pingback: AVI Developing Swine Flu Drugs | Xconomy | Medic Blog
Pingback: AVI Developing Swine Flu Drugs | Xconomy | SWINE BIRD FLU
Pingback: AVI Developing Swine Flu Drugs | Xconomy | Swine Flu Blog on Updates Outbreaks and Cure
Pingback: AVI Developing Swine Flu Drugs | Xconomy | Swine Flu In 2009